Amitriptyline-Grindex 25 mg is used in the treatment of depressions of any etiology. Due to its pronounced sedative effect, it is especially effective in depressive conditions accompanied by anxiety.
Active ingredient:
Each coated tablet contains 25 mg of amitriptyline hydrochloride.
Excipients:
Coated 25 mg tablets contain lactose, corn starch, polyvinylpyrrolidone, silicon dioxide, magnesium stearate; coating: blue dye - Opadry II Blue, carnauba wax.
Use only as directed by a physician.
Depression of any etiology. Particularly effective in depressive states accompanied by anxiety due to its sedative effect;
Mixed emotional disorders and behavioral disturbances; phobic fears;
Childhood enuresis (except in children with hypotonic bladder);
Psychogenic anorexia, bulimia nervosa;
Chronic pain syndrome (neurogenic in nature), migraine prophylaxis.
Decompensated heart failure;
Acute and recovery phase of myocardial infarction;
Cardiac conduction disturbances;
Stage III hypertension;
Severe liver and kidney diseases with marked functional impairment;
Blood disorders;
Active peptic ulcer disease of the stomach and duodenum;
Prostatic hypertrophy;
Bladder atony;
Pylorostenosis, paralytic intestinal obstruction;
Concurrent treatment with monoamine oxidase inhibitors (MAOIs);
Pregnancy, breastfeeding;
Children under 6 years of age (injectable forms are for 12 years and older);
Hypersensitivity to amitriptyline.
Administer orally (during or after meals).
The initial daily oral dose is 50-75 mg (25 mg 2-3 times a day), gradually increasing by 25-50 mg until the desired antidepressant effect is achieved. The optimal therapeutic daily dose is 150-200 mg (the largest part of the dose is taken at night). For treatment-resistant severe depression, doses may be increased up to 300 mg or more, up to the maximum tolerated dose (the maximum dose for outpatients is 150 mg/day). In such cases, it is advisable to start treatment with intramuscular or intravenous administration with higher initial doses and faster dose escalation under somatic condition monitoring.
After a stable antidepressant effect is achieved, doses are gradually and slowly reduced over 2-4 weeks. If signs of depression appear during dose reduction, it is necessary to return to the initial dose.
If the patient's condition does not improve after 3-4 weeks of treatment, further continuation is not recommended.
For elderly patients with mild disorders in outpatient practice, doses are 25-50-100 mg (maximum) divided or once daily at bedtime.
For children over 6 years with enuresis, 12.5-25 mg at bedtime (the dose should not exceed 2.5 mg/kg of body weight).
For migraine prophylaxis and neurotic chronic pain (including prolonged headaches), 12.5-25 mg up to 100 mg daily.
Store in a dry, dark place at a temperature not exceeding 25°C. Keep out of reach of children!
